The Data and Safety Monitoring Board approves the usage of high-dose ProTrans in the ongoing clinical trial

With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt. Discussions are currently underway between the boards of NextCell Pharma AB and Idogen AB regarding a potential merger. The structure being discussed would entail that NextCell Pharma AB makes a bid for all of the shares in Idogen AB and in turn will offer its own shares as a means of payment. At the time of the press release, the dialogue between the companies has only

NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adults. The company has previously been authorized by IVO to operate a tissue establishment using cells from the umbilical-cord and umbilical-cord-blood from newborns and operates a biobank for family saving of these cells. The extended approval state of fat-derived stem cells means for the fat-derived

The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social benefits that research of KI has contributed during the past 20 years. Cellaviva was founded by researchers at Karolinska Institutet with help from Karolinska Institutet Innovations AB. The company became the first private stem cell bank in

NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations. NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project, both funded by Vinnova. The work conducted in the projects is a collaborative effort between different types of stakeholders, such as SMEs, big pharma and county councils, all with the common goal of improving the Swedish conditions for innovative cell therapies. The latest development is that

NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's customer inflow has been increasing. ProTrans-1, NXTCL's ongoing clinical trial for the treatment of type-1 diabetes, is divided into two parts, the first being a three-step dose escalation with three patients in each step, a

NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist. The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with both its stem cell banking and drug development business is an ideal candidate for this list. The company develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any medical

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies. The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Swedish Research Council) and Sweden´s six healthcare regions, brings together researchers, politicians, and others who are active in the Life Science area. The scope of the event is knowledge exchange and networking, with the topic for the year being “The Value of Clinical studies”. Examples of issues

Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark. Cellaviva offers new parents the opportunity to save their child´s stem cells for therapeutic treatment of diseases the family has suffered from, or risk being affected of in the future. Stem cells are collected from the umbilical cord after the umbilical cord has been cut